0
0
As urban India grapples with rising lifestyle diseases, a new wave of weight-loss and diabetes drugs—Ozempic, Wegovy, Mounjaro, and Rybelsus—are not just rewriting medical records, but quietly transforming the country’s relationship with food. Once gastronomic hotspots, Indian cities now see a subtle shift among a growing cohort who, under the influence of these GLP-1 agonist medications, find age-old culinary cravings replaced by indifference—even aversion—toward all things delicious.
The Science Behind the Shift
GLP-1 agonists, recently launched or gaining momentum in India, act by mimicking a gut hormone that increases satiety and slows digestion. Patients often report feeling full after just a few bites—a striking departure from previous patterns that favored quantity and variety. While originally developed to manage diabetes, these drugs are now widely prescribed, or in some cases, sought online for their weight-loss benefits.
Changed Palates and New Habits
For many, the effects are dramatic. Rakesh Goyal, a 67-year-old businessman, saw his favorite Sunday treat, chhole-bhature, lose its appeal after two months on Mounjaro. “I don’t want to glance at chhole-bhature now, nor poori-bhaji nor dal baati,” he admits. His story is echoed by countless others—some finding freedom from constant food cravings, others lamenting the fading joy of shared meals and exotic tastes.
The ripple effects are visible far beyond kitchens. Urban restaurants and packaged food companies, accustomed to hearty orders and indulgent repeat customers, are beginning to notice reduced portion sizes and increasing demand for healthier, protein-rich options among a select but expanding audience.
Restaurant Industry Responds—Cautiously
While industry leaders like First Fiddle Restaurants anticipate a potential need for “Mounjaro menus” with smaller portions, they remain pragmatic. “It’s too early to predict demand trends, but it is bound to pick up,” says Priyank Sukhija, the group’s CEO. Others, like Zorawar Kalra of Massive Restaurants, see no immediate risk, citing the limited uptake of these medications beyond select urban clusters.
Executives in the packaged snacks sector echo this sentiment, viewing the boom as a niche trend among affluent city dwellers given the current weekly costs (Mounjaro 2.5mg starts at ₹3,500) and the specialized nature of the drugs.
Side Effects, New Joys, Hidden Costs
The benefits, say both doctors and patients, are not just about the numbers on a scale. “People who were addicted to sweets or fried food find their taste has changed,” notes Dr. Ambrish Mithal, one of India’s top endocrinologists. For many, mobility, confidence, and self-esteem improve as weight drops. But deprivation can take a toll: a minority develop an aversion to food, to alcohol, or even struggle with eating disorders as their relationship with eating turns transactional rather than pleasurable.
Looking Ahead
With Indian pharma giants preparing to launch generic versions as patents expire in 2026, accessibility—and debate—around these drugs will only intensify. While some celebrate the ability to conquer food addictions and reclaim health, others worry about the fading joy of food as culture and comfort. The transformation is subtle but seismic, with India’s urban foodscape at a historic crossroads.
Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider with any questions regarding nutrition, medications, or treatment options.
Reference: Adapted from the original report, “Food Chained: How weight-loss drugs are changing India’s eating habits and forcing restaurants to take note” published by ET HealthWorld on August 2025.
